Drug Trial Radar · NCT00059306
Secondary Prevention of Small Subcortical Strokes Trial
Last checked: Nov 19, 2026Latest source record: Apr 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,020
Actual
Start
Feb 2003
Primary completion
Apr 2012
Study completion Apr 2012
Sponsor
- Lead sponsor
- University of British ColumbiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Apr 24, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline. On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.
Conditions
- Cerebrovascular Accident
- Hypertension
Interventions
aspirinDrug
Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
clopidogrelDrug
Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
Target of Blood PressureOther
Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
placeboOther
an inactive substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evidence of clinically defined ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by non-investigational CT or MRITime frame: Mean follow up of 4 years
- Evidence of hemorrhagic stroke; a neurologic deficit associated with intraparenchymal or subarachnoid space lesion on CT/MRI or cerebral hemorrhage demonstrated by surgery or autopsy.Time frame: within mean follow-up of 4 years
Locations
63 sites in 7 countries. Site status is shown where the registry gives one.
University of Southern Alabama Stroke Center
Mobile, Alabama
Catholic Healthcare West
Phoenix, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona
University of Arizona, Department of Neurology
Tucson, Arizona
University of California San Diego Medical Center
San Diego, California
University of California San Francisco-Fresno
San Francisco-Fresno, California
Denver
Englewood, Colorado
Melbourne
Melbourne, Florida
Miami-University of Miami, Miller School of Medicine
Miami, Florida
Emory University, Grady Health System
Atlanta, Georgia
Mercy Medical Center-Ruan Neurology Clinical Research
Des Moines, Iowa
University of Kentucky, Aging/Stroke Program
Lexington, Kentucky
Suburban Hospital
Bethesda, Maryland
Boston University
Boston, Massachusetts
Wayne State
Detroit, Michigan
Henry Ford Hospital, Department of Neurology
Detroit, Michigan
Berman Center
Minneapolis, Minnesota
Mayo Stroke Center KA-SL-13
Rochester, Minnesota
University of Washington
Sant Louis, Missouri
Tenet Health, St. Louis University
St Louis, Missouri
St. John's Mercy
St Louis, Missouri
Cooper University Hospital
Camden, New Jersey
Buffalo
Buffalo, New York
Helen Hayes Hospital
Haverstraw, New York
Columbia University Medical Center
New York, New York
Rochester General Hospital
Rochester, New York
University of Rochester
Rochester, New York
Wake Forest University, Sciences-Neurology
Winston-Salem, North Carolina
Case Western
Cleveland, Ohio
Metrohealth Medical Center
Cleveland, Ohio
Ohio State University, Division of Stroke
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern
Dallas, Texas
Scurlock Stroke Center
Houston, Texas
University of Texas Health Science Center
San Antonio, Texas
University of Washington
Seattle, Washington
Marshfield Clinic, Department of Neurology
Marshfield, Wisconsin
Medical College of Wisconsin-Neurology
Milwaukee, Wisconsin
Calgary Health
Calgary, Alberta, Canada
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.